## Stephen R Chapman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2550975/publications.pdf

Version: 2024-02-01

40 papers 435

11 h-index 752698 20 g-index

43 all docs

43 docs citations

times ranked

43

555 citing authors

#	Article	IF	Citations
1	Developing a model Fracture Liaison Service consultation with patients, carers and clinicians: a Delphi survey to inform content of the iFraP complex consultation intervention. Archives of Osteoporosis, 2021, 16, 58.	2.4	7
2	Shared Decision-Making With a Virtual Patient in Medical Education: Mixed Methods Evaluation Study. JMIR Medical Education, 2021, 7, e22745.	2.6	4
3	Improving uptake of Fracture Prevention drug treatments: a protocol for Development of a consultation intervention (iFraP-D). BMJ Open, 2021, 11, e048811.	1.9	6
4	Impact of the introduction of falls risk assessment toolkit on falls prevention and psychotropic medicines' utilisation in Walsall: an interrupted time series analysis. BMJ Open, 2021, 11, e039649.	1.9	0
5	Experiencing a virtual patient to practice patient counselling skills. Currents in Pharmacy Teaching and Learning, 2021, 13, 1593-1601.	1.0	4
6	Establishing the acceptability and usability of an animated virtual patient simulation. Exploratory Research in Clinical and Social Pharmacy, 2021, 4, 100069.	1.0	2
7	Virtual patient technology to educate pharmacists and pharmacy students on patient communication: a systematic review. BMJ Simulation and Technology Enhanced Learning, 2020, 6, 332-338.	0.7	15
8	Actual vs. Perceived Competency Development—How Can Virtual Patients Impact Pharmacist Pre-Registration Training?. Pharmacy (Basel, Switzerland), 2020, 8, 138.	1.6	3
9	Virtual patients as a tool for training pre-registration pharmacists and increasing their preparedness to practice: A qualitative study. PLoS ONE, 2020, 15, e0238226.	2.5	8
10	Interactive Clinical Avatar Use in Pharmacist Preregistration Training: Design and Review. Journal of Medical Internet Research, 2020, 22, e17146.	4.3	6
11	Title is missing!. , 2020, 15, e0238226.		0
12	Title is missing!. , 2020, 15, e0238226.		0
13	Title is missing!. , 2020, 15, e0238226.		O
14	Title is missing!. , 2020, 15, e0238226.		0
15	Title is missing!. , 2020, 15, e0238226.		0
16	Title is missing!. , 2020, 15, e0238226.		0
17	The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis. Research in Social and Administrative Pharmacy, 2019, 15, 310-317.	3.0	35
18	Virtual patient educational programme to teach counselling to clinical pharmacists: development and proof of concept. BMJ Simulation and Technology Enhanced Learning, 2019, 5, 167-169.	0.7	10

#	Article	IF	Citations
19	Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysis. BMJ Open, 2019, 9, e026817.	1.9	4
20	Differences in UK healthcare professionals' knowledge, attitude and practice towards infliximab and insulin glargine biosimilars. International Journal of Pharmacy Practice, 2019, 27, 214-217.	0.6	17
21	Virtual patient educational intervention for the development of shared decision-making skills: a pilot study. BMJ Simulation and Technology Enhanced Learning, 2019, 5, 215-217.	0.7	2
22	Healthcare professionals' perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study. BMJ Open, 2018, 8, e023603.	1.9	39
23	Improving Shared Decision Making Between Patients and Clinicians: Design and Development of a Virtual Patient Simulation Tool. JMIR Medical Education, 2018, 4, e10088.	2.6	16
24	Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey. BMJ Open, 2017, 7, e016730.	1.9	41
25	What drives the prescribing of growth hormone preparations in England? Prices versus patient preferences. BMJ Open, 2017, 7, e013730.	1.9	5
26	Has cost inhibited the uptake of more potent statins in England?. Pharmacoepidemiology and Drug Safety, 2017, 26, 984-991.	1.9	6
27	Patients' Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey. BioDrugs, 2017, 31, 439-446.	4.6	24
28	Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. BioDrugs, 2017, 31, 533-544.	4.6	45
29	Falls and the rise of the GP contract: An EMIS web protocol and template to help identify frail patients. British Journal of Community Nursing, 2017, 22, 554-556.	0.4	5
30	Survey of patients' experiences and perceptions of care provided by nurse and pharmacist independent prescribers in primary care. Health Expectations, 2015, 18, 1241-1255.	2.6	34
31	Safety, trust, and money are uncomfortable bedfellows. BMJ, The, 2015, 351, h5750.	6.0	2
32	Making decisions about prescribing in diabetes. Practice Nursing, 2008, 19, 128-131.	0.1	3
33	ORCA: a new tool for the review of medication in asthma management. NursePrescribing, 2004, 2, 20-24.	0.1	3
34	Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care. BMJ: British Medical Journal, 2003, 326, 707-709.	2.3	41
35	Pharma focus. Puff adders. The Health Service Journal, 2003, 113, suppl 6-7.	0.0	0
36	Managing medicines: Dyspepsia. Practice Nursing, 1996, 7, 39-42.	0.1	0

## STEPHEN R CHAPMAN

#	Article	IF	CITATIONS
37	Managing medicines: NSAIDs. Practice Nursing, 1996, 7, 37-41.	0.1	O
38	Medicines: Drugs for asthma. Practice Nursing, 1996, 7, 39-42.	0.1	2
39	Managing medicines: Antibiotics. Practice Nursing, 1996, 7, 38-42.	0.1	O
40	Is the ratio of inhaled corticosteroid to bronchodilator a good indicator of the quality of asthma prescribing? Cross sectional study linking prescribing data to data on admissions. BMJ: British Medical Journal, 1996, 313, 1124-1126.	2.3	43